INNOPEA®

INNOPEA® is a dietary supplement with palmitoylethanolamide and B vitamins that contribute to normal nervous and immune system function, normal psychological function, as well as reducing fatigue and exhaustion. Thanks to its specific patented formulation, INNOPEA® contributes to the reduction of oxidative stress in chronic painful and inflammatory conditions, stimulation of the immune system and faster body recovery.

INNOPEA® thanks to its unique mechanism of action, reduces inflammation in acute and chronic inflammation, reduces the intensity of acute and chronic pain, regulates the immune response, as well as contributes to the protection of nerve cells, optimizing cognitive functions and improving quality of life.

In which conditions is the use of the product INNOPEA® recommended?

Why INNOPEA®?

What does INNOPEA® contain?

Active ingredients
1 sachet (2g)
Levagen®+
350 mg
out of which palmitoylethanolamide
315 mg
Vitamin B1 (thiamine-hydrochloride)
0,55 mg
Vitamin B6 (pyridoxine-hydrochloride)
0,70 mg
Vitamin B12 (methylcobalamin)
1,25 µg
INNOPEA® 350 mg ≈ Standard PEA 600 mg
Palmitoylethanolamide has a dose-dependent effect during administration.
Higher dose provides for better therapeutic response5.

Method of use

Adults: Dissolve the contents of the sachet in a glass of water and drink, in the morning and evening, or dissolve the contents of the sachet directly in the mouth, without adding liquid, in the morning and evening, for the first 15 days. After that, continue administration once a day.
Presentation: 15 sachets with sweetener and raspberry flavour.

Levagen®+

Levagen®+ is a patented formulation containing palmitoylethanolamide produced by a special LipiSperse® technology that increases the absorption of lipophilic active substances. LipiSperse® “coating system” coats PEA molecules, which reduces hydrophobic properties and enables: Sperse® technology that increases the absorption of lipophilic active substances. LipiSperse® “coating system” coats PEA molecules, which reduces hydrophobic properties and enables:

INNOPEA® 350 mg ≈ Standard PEA 600 mg
Palmitoylethanolamide has a dose-dependent effect during administration.
Higher dose provides for better therapeutic response5.

PHARMACOKINETIC STUDY

Design: Paralel, double blind bioavailability study measuring the concentration of PEA over the period of 24 hours after intake of 300 mg of standard PEA or 300 mg of PEA produced by LipiSperse® technology on healthy subjects (n=28).

Levagen®+

Levagen®+ is a patented formulation containing palmitoylethanolamide produced by a special LipiSperse® technology that increases the absorption of lipophilic active substances. LipiSperse® “coating system” coats PEA molecules, which reduces hydrophobic properties and enables: Sperse® technology that increases the absorption of lipophilic active substances. LipiSperse® “coating system” coats PEA molecules, which reduces hydrophobic properties and enables:

INNOPEA® 350 mg ≈ Standard PEA 600 mg
Palmitoylethanolamide has a dose-dependent effect during administration.
Higher dose provides for better therapeutic response5.

PHARMACOKINETIC STUDY

Design: Paralel, double blind bioavailability study measuring the concentration of PEA over the period of 24 hours after intake of 300 mg of standard PEA or 300 mg of PEA produced by LipiSperse® technology on healthy subjects (n=28).